As overexpression of AXL/GAS6 can contribute to tumor invasion, metastasis especially to the brain, and drug resistance against chemotherapy and targeted therapies in NSCLC, the AXL/GAS6 pathway can be promising therapeutic target for clinical inhibition. The gene discussed is GAS6; the disease is neoplasm.